Industry news from Neurokinex
EU approval of Mayzent® (siponimod) for adult patients with secondary progressive multiple sclerosis (SPMS) with active disease
News from Novartis on the EU approval of Mayzent (siponimod) for adult patients with SPMS with active disease
Phase II clinical trial of respiratory drug for treatment of Parkinson’s reveals promising results
News from the Cure Parkinson’s Trust
Ocrelizumab (Ocrevus®) accepted for use in PPMS within NHS Scotland
Industry news from Roche
Fremanezumab: Chronic and episodic migraine medication approved for use within NHS Scotland
Industry news from Teva Pharmaceuticals
ATAI Life Sciences partners to reduce the impact of concussion on and off the field
News from ATAI and Neuronasal
Spravato®▼ (Esketamine) Nasal Spray authorised in Europe for Adults with Treatment-Resistant Major Depressive Disorder
Industry news from Janssen
Fampyra® (fampridine) becomes first symptomatic treatment in Wales to receive a recommendation for funding as an option for walking impairment in adult patients with all types of multiple sclerosis (MS)
Industry news from Biogen
Grifols presents latest Alzheimer’s clinical trial data
Neuroimaging shows AMBAR clinical trial’s positive effects in patients with mild-to-moderate Alzheimer’s disease
